Platform & Strategies
Publications
HomePlatform & StrategiesPublications
| NO | Pipeline | Name | Title | |
|---|---|---|---|---|
| 15 | ABL103 | AACR 2022 | AACR 2022 / A novel T-cell engaging bispecific antibody, exhibits potent in vitro and vivoantitumor activity and low toxicity via B7-H4 dependent 4-1BB activation in tumor microenvironment |
|
| 14 | ABL602 | ASH2021 | ASH2021 / A novel asymmetrical anti-CLL-1×CD3 bispecific antibody, ABL602, induces potent CLL1-specific antitumor activity with minimized sensitization of pro-inflammatory cytokines |
|
| 13 | ABL503 | SITC2021 | SITC2021 / ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8 + T cells in tumor microenvironment |
|
| 12 | ABL111 | SITC2021 | SITC2021 / TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumordependent immune response without dose-limiting toxicity in preclinical studies |
|
| 11 | ABL103 | PEGS Europe 2021 | PEGS Europe 2021 / A novel T-cell engaging bispecific antibody, ABL103, shows potent anti-tumor effect via B7-H4 mediated 4-1BB activation in TME |
|
| 10 | ABL105 | ESMO2021 | ESMO2021 / A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation |
|
| 9 | 4-1BB Platform | AACR 2021 | AACR 2021 / A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format |
|
| 8 | ABL501 | AACR2021 | AACR2021 / ABL501 (PD-L1xLAG-3), a bispecific antibody promotes enhanced human T cell activation through targeting simultaneously two immune checkpoint inhibitors, LAG-3 and PD-L1 |
|
| 7 | Grabody T | AACR2021 | AACR2021 / A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format |
|
| 6 | 4-1BB Platform | AACR 2020 | AACR 2020 / B7-H3-targeted 4-1BB activation potentiates CD8 T cell-dependent antitumor immunity without systemic toxicity |
|
-
AACR 2022 / A novel T-cell engaging bispecific antibody, exhibits potent in vitro and vivoantitumor activity and low toxicity via B7-H4 dependent 4-1BB activation in tumor microenvironment
-
ASH2021 / A novel asymmetrical anti-CLL-1×CD3 bispecific antibody, ABL602, induces potent CLL1-specific antitumor activity with minimized sensitization of pro-inflammatory cytokines
-
SITC2021 / ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8 + T cells in tumor microenvironment
-
SITC2021 / TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumordependent immune response without dose-limiting toxicity in preclinical studies
-
PEGS Europe 2021 / A novel T-cell engaging bispecific antibody, ABL103, shows potent anti-tumor effect via B7-H4 mediated 4-1BB activation in TME
-
ESMO2021 / A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation
-
AACR 2021 / A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format
-
AACR2021 / ABL501 (PD-L1xLAG-3), a bispecific antibody promotes enhanced human T cell activation through targeting simultaneously two immune checkpoint inhibitors, LAG-3 and PD-L1
-
AACR2021 / A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format
-
AACR 2020 / B7-H3-targeted 4-1BB activation potentiates CD8 T cell-dependent antitumor immunity without systemic toxicity